Clinical summary
Summary
This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.Age
18+
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Pharmacyclics
Scientific Title
Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma